Frye Robert L, Bell Malcolm R, Schaff Hartzell V, Holubkov Richard, Detre Katherine M
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Curr Diab Rep. 2002 Feb;2(1):16-20. doi: 10.1007/s11892-002-0052-z.
The role of percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) in patients with diabetes mellitus (DM) is evolving. Data from clinical trials and observational studies are reviewed as well as current clinical practice guidelines. The importance of aggressive medical therapy to achieve recommended glycemic control targets, and management of usual risk factors in patients with coronary artery disease (CAD) cannot be overemphasized regardless of the revascularization therapy selected. Patients with type 2 diabetes are at increased risk for CAD, which is the cause of death in the majority of patients. Outcomes following PCI and CABG are worse in patients with DM compared to those without DM. This calls for randomized trials and other studies focused on patients with DM.
经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)在糖尿病(DM)患者中的作用正在不断演变。本文回顾了来自临床试验和观察性研究的数据以及当前的临床实践指南。无论选择何种血运重建治疗,积极的药物治疗以实现推荐的血糖控制目标以及对冠心病(CAD)患者常见危险因素的管理都至关重要。2型糖尿病患者患CAD的风险增加,CAD是大多数患者的死亡原因。与非糖尿病患者相比,糖尿病患者PCI和CABG后的预后更差。这就需要针对糖尿病患者开展随机试验和其他研究。